Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keytruda's Broad Confirmatory Trials Suggest Evolution Of US FDA’s Accelerated Approval Model

Jun 21 2018

• By Michael Cipriano

Related Content

Keeping Track: <em>Tecentriq</em>, <em>Opdivo</em> Approvals Intensify Spotlight On Immuno-Oncology

May 23 2016

Keytruda NSCLC Approval Will Test PD-L1 Expression

Oct 02 2015

Bristol Hits Sweet Spot On Checkpoint Inhibitor Combination Pricing

Oct 01 2015

Keeping Track: Immuno-Oncology Racks Up More Approvals; Bar Still Too High For Advair Generics

May 15 2017

AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon

May 01 2017

Keeping Track: Keytruda Adds Two New Uses, Furoscix ‘Patch Pump’ Gets A CRL, And Nightstar Nabs An RMAT

Jun 15 2018

What We Talk About When We Talk About Confirmatory Evidence

Jun 15 2017

Related Companies

Merck & Co., Inc.

Seagen Inc.

Merck KGaA

Pfizer Inc.

AstraZeneca PLC

Bristol Myers Squibb Company

Genentech, Inc.

Additional Topics

United States Approvals Post Market Regulation & Studies Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window